Abstract
Antitumor strategies based on positive modulation of the immune system currently represent therapeutic options with prominent acceptance for cancer patients’ treatment due to its selectivity and higher tolerance compared to chemotherapy. Racotumomab is an anti-idiotype (anti-Id) monoclonal antibody (mAb) directed to NeuGc-containing gangliosides such as NeuGcGM3, a widely reported tumor-specific neoantigen in many human cancers. Racotumomab has been approved in Latin American countries as an active immunotherapy for advanced non-small cell lung cancer (NSCLC) treatment. In this work, we evaluated the induction of Ab-dependent cell-mediated cytotoxicity (ADCC) in NSCLC patients included in a phase III clinical trial, in response to vaccination with racotumomab. The development of anti-NeuGcGM3 antibodies (Abs) in serum samples of immunized patients was first evaluated using the NeuGcGM3-expressing X63 cells, showing that racotumomab vaccination developed antigen-specific Abs that are able to recognize NeuGcGM3 expressed in tumor cell membranes. ADCC response against NeuGcGM3-expressing X63 (target) was observed in racotumomab-treated- but not in control group patients. When target cells were depleted of gangliosides by treatment with a glucosylceramide synthase inhibitor, we observed a significant reduction of the ADCC activity developed by sera from racotumomab-vaccinated patients, suggesting a target-specific response. Our data demonstrate that anti-NeuGcGM3 Abs induced by racotumomab vaccination are able to mediate an antigen-specific ADCC response against tumor cells in NSCLC patients.
Similar content being viewed by others
Abbreviations
- ADCC:
-
Antibody-dependent cell-mediated cytotoxicity
- Anti-id:
-
Anti-idiotype
- PDMP:
-
d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
References
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594. https://doi.org/10.4065/83.5.584
Tabchi S, Blais N, Campeau MP, Tehfe M (2017) Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer. Cancer Chemother Pharmacol 79(2):381–387. https://doi.org/10.1007/s00280-016-3226-0
Jackman DM, Miller VA, Cioffredi L-A, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15 (16):5267
Somasundaram A, Burns TF (2017) Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Lung Cancer 8:1–11. https://doi.org/10.2147/LCTT.S105678
Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG (2009) The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11(5):448–458 (442 p following 458)
Pillay V, Gan HK, Scott AM (2011) Antibodies in oncology. N Biotechnol 28(5):518–529. https://doi.org/10.1016/j.nbt.2011.03.021
Konitzer JD, Sieron A, Wacker A, Enenkel B (2015) Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro. PLoS One 10(12):e0145633. https://doi.org/10.1371/journal.pone.0145633
Gong Q, Hazen M, Marshall B, Crowell SR, Ou Q, Wong AW, Phung W, Vernes JM, Meng YG, Tejada M, Andersen D, Kelley RF (2016) Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation. MAbs 8(6):1098–1106. https://doi.org/10.1080/19420862.2016.1189049
Lesterhuis WJ, Haanen JBAG, Punt CJA (2011) Cancer immunotherapy—revisited. Nat Rev Drug Discov 10(8):591–600
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fucikova J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jager D, Kalinski P, Karre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautes-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G (2014) Classification of current anticancer immunotherapies. Oncotarget 5(24):12472–12508. https://doi.org/10.18632/oncotarget.2998
Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM (2015) NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 6:368. https://doi.org/10.3389/fimmu.2015.00368
Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199(12):1659–1669. https://doi.org/10.1084/jem.20040119
Biburger M, Aschermann S, Schwab I, Lux A, Albert H, Danzer H, Woigk M, Dudziak D, Nimmerjahn F (2011) Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35(6):932–944. https://doi.org/10.1016/j.immuni.2011.11.009
Lanier LL, Ruitenberg JJ, Phillips JH (1988) Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 141(10):3478–3485
Metes D, Manciulea M, Pretrusca D, Rabinowich H, Ernst LK, Popescu I, Calugaru A, Sulica A, Chambers WH, Herberman RB, Morel PA (1999) Ligand binding specificities and signal transduction pathways of Fc gamma receptor IIc isoforms: the CD32 isoforms expressed by human NK cells. Eur J Immunol 29(9):2842–2852. https://doi.org/10.1002/(SICI)1521-4141(199909)29:09<2842::AID-IMMU2842>3.0.CO;2-5
Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S (2007) Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121(3):392–404. https://doi.org/10.1111/j.1365-2567.2007.02588.x
Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278–287. https://doi.org/10.1038/nrc3236
Seidel UJ, Schlegel P, Lang P (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 4:76. https://doi.org/10.3389/fimmu.2013.00076
Vazquez AM, Perez A, Hernandez AM, Macias A, Alfonso M, Bombino G, Perez R (1998) Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 17(6):527–534
Alfonso S, Valdes-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernandez M, Viada CE, Mendoza IC, Guerra PP, Garcia E, Ortiz RA, de la Torre AV, Cepeda M, Perez K, Chong E, Hernandez AM, Toledo D, Gonzalez Z, Mazorra Z, Crombet T, Perez R, Vazquez AM, Macias AE (2014) A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 20(14):3660–3671. https://doi.org/10.1158/1078-0432.CCR-13-1674
Gabri MR, Cacciavillano W, Chantada GL, Alonso DF (2016) Racotumomab for treating lung cancer and pediatric refractory malignancies. Expert Opin Biol Ther 16(4):573–578. https://doi.org/10.1517/14712598.2016.1157579
van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G (2009) Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 9:180. https://doi.org/10.1186/1471-2407-9-180
Blanco R, Rengifo CE, Cedeno M, Frometa M, Rengifo E, Carr A (2012) Immunoreactivity of the 14F7 Mab (Raised against N-glycolyl GM3 ganglioside) as a positive prognostic factor in non-small-cell lung cancer. Patholog Res Int 2012:235418. https://doi.org/10.1155/2012/235418
Blanco R, Dominguez E, Morales O, Blanco D, Martinez D, Rengifo CE, Viada C, Cedeno M, Rengifo E, Carr A (2015) Prognostic significance of N-Glycolyl GM3 ganglioside expression in non-small cell lung carcinoma patients: new evidences. Patholog Res Int 2015:132326. https://doi.org/10.1155/2015/132326
Fuentes D, Avellanet J, Garcia A, Iglesias N, Gabri MR, Alonso DF, Vazquez AM, Perez R, Montero E (2010) Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res Treat 120(2):379–389. https://doi.org/10.1007/s10549-009-0399-9
Diaz Y, Gonzalez A, Lopez A, Perez R, Vazquez AM, Montero E (2009) Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 58(7):1117–1128. https://doi.org/10.1007/s00262-008-0634-y
Segatori VI, Vazquez AM, Gomez DE, Gabri MR, Alonso DF (2012) Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol 2:160. https://doi.org/10.3389/fonc.2012.00160
Hernandez AM, Rodriguez N, Gonzalez JE, Reyes E, Rondon T, Grinan T, Macias A, Alfonso S, Vazquez AM, Perez R (2011) Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol 186(6):3735–3744. https://doi.org/10.4049/jimmunol.1000609
Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C, Rengifo E, Perez R, Fernandez LE (2000) A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 19(3):241–247. https://doi.org/10.1089/02724570050109639
Muthing J, Steuer H, Peter-Katalinic J, Marx U, Bethke U, Neumann U, Lehmann J (1994) Expression of gangliosides GM3 (NeuAc) and GM3 (NeuGc) in myelomas and hybridomas of mouse, rat, and human origin. J Biochem 116(1):64–73
Fedoryszak-Kuska N, Panasiewicz M, Domek H, Pacuszka T (2016) Glucosylceramide synthase inhibitors D-PDMP and D-EtDO-P4 decrease the GM3 ganglioside level, differ in their effects on insulin receptor autophosphorylation but increase Akt1 kinase phosphorylation in human hepatoma HepG2 cells. Acta Biochim Pol 63(2):247–251. https://doi.org/10.18388/abp.2014_930
Wei XX, Fong L, Small EJ (2015) Prostate cancer immunotherapy with sipuleucel-T: current standards and future directions. Expert Rev Vaccines 14(12):1529–1541. https://doi.org/10.1586/14760584.2015.1099437
van den Eertwegh AJM, Versluis J, van den Berg HP, Santegoets SJAM, van Moorselaar RJA, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AGM, von Blomberg BME, de Gruijl TD, Hege K, Sacks N, Gerritsen WR (2012) Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13(5):509–517. https://doi.org/10.1016/S1470-2045(12)70007-4
Le DT, Jaffee EM (2013) Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 11(7):766–772. https://doi.org/10.6004/jnccn.2013.0099
Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A (1998) The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 273(25):15866–15871
Oliva JP, Valdés Z, Casacó A, Pimentel G, González J, Álvarez I, Osorio M, Velazco M, Figueroa M, Ortiz R, Escobar X, Orozco M, Cruz J, Franco S, Díaz M, Roque L, Carr A, Vázquez AM, Mateos C, Rubio MC, Pérez R, Fernández LE (2006) Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc. Breast Cancer Res Treat 96(2):115–121. https://doi.org/10.1007/s10549-005-9064-0
Torbidoni AV, Scursoni A, Camarero S, Segatori V, Gabri M, Alonso D, Chantada G, de Davila MT (2015) Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 ganglioside in retinoblastoma tumours. Acta Ophthalmol 93(4):e294–e300. https://doi.org/10.1111/aos.12578
Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, Segatori VI, Gabri MR, Alonso DF, Chantada G, de Dávila MTG (2011) Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol 2011:245181. https://doi.org/10.1155/2011/245181
Vamecq J, Mestdagh N, Henichart JP, Poupaert J (1992) Subcellular distribution of glycolyltransferases in rodent liver and their significance in special reference to the synthesis of N-glycolylneuraminic acid. J Biochem 111(5):579–583
Malykh YN, Schauer R, Shaw L (2001) N-Glycolylneuraminic acid in human tumours. Biochimie 83(7):623–634. https://doi.org/10.1016/S0300-9084(01)01303-7
Bardor M, Nguyen DH, Diaz S, Varki A (2005) Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 280(6):4228–4237
Yin J, Hashimoto A, Izawa M, Miyazaki K, Chen GY, Takematsu H, Kozutsumi Y, Suzuki A, Furuhata K, Cheng FL, Lin CH, Sato C, Kitajima K, Kannagi R (2006) Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 66(6):2937–2945. https://doi.org/10.1158/0008-5472.CAN-05-2615
Segatori VI, Otero LL, Fernandez LE, Gomez DE, Alonso DF, Gabri MR (2012) Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides. In Vivo 26(4):609–617
Gabri MR, Otero LL, Gomez DE, Alonso DF (2009) Exogenous incorporation of neugc-rich mucin augments N-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. J Exp Clin Cancer Res 28:146. https://doi.org/10.1186/1756-9966-28-146
de Leon J, Fernandez A, Mesa C, Clavel M, Fernandez LE (2006) Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 55(4):443–450. https://doi.org/10.1007/s00262-005-0041-6
de León J, Fernández A, Clavell M, Labrada M, Bebelagua Y, Mesa C, Fernández LE (2008) Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+ CD25—effector and naturally occurring CD4+ CD25+ regulatory T cells function. Int Immunol 20(4):591–600. https://doi.org/10.1093/intimm/dxn018
Alfonso M, Diaz A, Hernandez AM, Perez A, Rodriguez E, Bitton R, Perez R, Vazquez AM (2002) An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 168(5):2523–2529
Díaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catalá M, Díaz RM, Pérez R, Vázquez AM (2003) Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107(2):80–89. https://doi.org/10.1016/S1521-6616(03)00036-6
Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vázquez AM, Fainboim L (2006) Cellular and humoral immune response to N-glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 29(2):215–223. https://doi.org/10.1097/01.cji.0000188502.11348.34
Alfonso S, Díaz RM, de la Torre A, Santiesteban E, Aguirre F, Pérez K, Rodríguez JL, Barroso MC, Hernández AM, Toledo D, Gabri MR, Alonso DF, Viada C, Gómez RE, Pestana E, Suarez E, Vázquez AM, Perez R, Macías A (2007) 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 6(12):1847–1852. https://doi.org/10.4161/cbt.6.12.5000
Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, Gabri MR, Alonso DF, Wilkinson B, Alfonso AM, Combet T, Perez R, Vázquez AM (2007) Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 6(2):145–150. https://doi.org/10.4161/cbt.6.2.3574
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443–446
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM (2010) Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. N Engl J Med 363(14):1324–1334. https://doi.org/10.1056/NEJMoa0911123
Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA (1991) Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51(1):144–149
Snijdewint FGM, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, Kenemans P (2001) Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 93(1):97–106. https://doi.org/10.1002/ijc.1286
Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon KA, Chatterjee SK (1997) Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res 57(4):728–734
Lode HN, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, Reker D, Brandt S, Mueller H-P, Helm C, Siebert N (2013) Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response. Cancer Immunol Immunother 62(6):999–1010. https://doi.org/10.1007/s00262-013-1413-y
Acknowledgements
The authors gratefully acknowledge Diego Mengual Gomez for his valuable support with the blood samples from healthy donors. The authors also thank Marina Pifano and Nazareno Gonzalez for their valuable contribution during the statistical analysis of the data. Valeria I Segatori and Héctor A Cuello are research fellows of ANPCyT (Argentina). Marina Albertó is a research fellow and Mariano R Gabri and Daniel F Alonso are members of the National Research Council (CONICET, Argentina).
Funding
This study was partially funded by National University of Quilmes (Grant No. 1398/15) and ELEA Laboratories.
Author information
Authors and Affiliations
Contributions
Valeria I. Segatori and Mariano R. Gabri participated in the conception and design of the experiments, the analysis and interpretation of data and in the process of manuscript writing. Héctor A. Cuello, Cynthia A. Gulino and Marina Albertó also contributed to the final version of the manuscript. Valeria I. Segatori, Héctor A. Cuello, Cynthia A. Gulino and Marina Albertó worked in development of methodology and acquisition of data. Cecilia Venier was involved in the ELISA assays. Marcelo D. Guthmann and Ignacio A. Demarco were responsible for patients’ samples. Review of the manuscript was done by Daniel F. Alonso and Mariano R. Gabri.
Corresponding author
Ethics declarations
Conflict of interest
Marcelo D. Guthmann and Ignacio A. Demarco are full employees of Elea Laboratories. They have no conflict of interest to declare. All other authors declare that they have no potential conflict of interest.
Ethical approval and ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Rights and permissions
About this article
Cite this article
Segatori, V.I., Cuello, H.A., Gulino, C.A. et al. Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients. Cancer Immunol Immunother 67, 1285–1296 (2018). https://doi.org/10.1007/s00262-018-2188-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-018-2188-y